Biogenesis aberration: One of the mechanisms of thrombocytopenia in COVID-19

Background: The pathogenesis of COVID-19, including thrombocytopenia, has not been fully clarified. The lungs are a major organ of platelet production and thrombocytopenia induced by severe COVID-19 was proposed.Methods: the change of platelet level was analysed with clinical parameters in 95 hospitalized COVID-19 patients in Wuhan Third Hospital. The production of platelets in the lungs was explored in an ARDS rat model.Results: The level of platelets was negatively correlated with disease severity and was recovered with disease improvement. The non-survivors were accompanied by lower levels of platelet. The odds ratio (OR) of the valley level of the platelet count (PLTlow) was greater than 1, suggesting that PLTlow could be a death exposure factor. The platelet/lymphocyte ratio (PLR) was positively associated with severity of COVID-19, and the platelet/lymphocyte ratio threshold of 248.5 was best correlated with death risk (sensitivity 0.641 and specificity 0.815). To demonstrate the possible biogenesis aberration of platelet in lungs, an LPS-induced ARDS rat model was applied. Lower level of platelet in peripheral and less production of platelet from lungs in ARDS were demonstrated. Though megakaryocyte (MK) number in ARDS lungs is higher than controls, the immature platelet fraction (IPF) in postpulmonary blood is still at the same level as prepulmonary in ARDS rat, indicating that ARDS rats generated fewer platelets in lungs.Conclusion: Our data suggested that COVID-19-induced severe lung inflammation may impair platelet production in the lung. Thrombocytopenia may be mainly caused by platelet consumption for multiorgan thrombosis; however, biogenesis aberration of platelet in the lung induced by diffuse interstitial pulmonary damage cannot be ruled out.

[1]  F. Ginhoux,et al.  Infection of lung megakaryocytes and platelets by SARS-CoV-2 anticipate fatal COVID-19 , 2022, Cellular and Molecular Life Sciences.

[2]  A. M. Salih,et al.  Accelerated heparin-induced thrombocytopenia in a COVID-19 patient; a case report with literature review , 2022, Annals of Medicine and Surgery.

[3]  G. Remuzzi,et al.  SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation , 2022, Frontiers in Immunology.

[4]  G. Narasimhan,et al.  Potential Autoimmunity Resulting from Molecular Mimicry between SARS-CoV-2 Spike and Human Proteins , 2022, bioRxiv.

[5]  F. Dèng,et al.  SARS-CoV-2 interacts with platelets and megakaryocytes via ACE2-independent mechanism , 2021, Journal of Hematology & Oncology.

[6]  Robert A. Campbell,et al.  COVID‐19 patients exhibit reduced procoagulant platelet responses , 2020, Journal of Thrombosis and Haemostasis.

[7]  Hong Chen,et al.  Ratios of neutrophil-to-lymphocyte and platelet-to-lymphocyte predict all-cause mortality in inpatients with coronavirus disease 2019 (COVID-19): a retrospective cohort study in a single medical centre , 2020, Epidemiology and Infection.

[8]  S. Drăghici,et al.  Platelets and renal failure in the SARS-CoV-2 syndrome , 2020, Platelets.

[9]  Shenmin Zhang,et al.  SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19 , 2020, Journal of Hematology & Oncology.

[10]  R. Bhandari,et al.  SARS-CoV-2 and pulmonary embolism: who stole the platelets? , 2020, Thrombosis Journal.

[11]  A. Borczuk,et al.  COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City , 2020, Modern Pathology.

[12]  T. Trenti,et al.  A proof of evidence supporting abnormal immunothrombosis in severe COVID-19: naked megakaryocyte nuclei increase in the bone marrow and lungs of critically ill patients , 2020, Platelets.

[13]  A. Granito,et al.  Coronavirus disease associated immune thrombocytopenia: Causation or correlation? , 2020, Journal of Microbiology, Immunology and Infection.

[14]  Javier M. Martín-López,et al.  Increased number of pulmonary megakaryocytes in COVID-19 patients with diffuse alveolar damage: an autopsy study with clinical correlation and review of the literature , 2020, Virchows Archiv.

[15]  S. Pittaluga,et al.  Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series , 2020, EClinicalMedicine.

[16]  Robert A. Campbell,et al.  Platelet gene expression and function in patients with COVID-19 , 2020, Blood.

[17]  P. Gibson,et al.  COVID‐19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre‐COVID‐19 ARDS , 2020, The Medical journal of Australia.

[18]  Xiaochun Ma,et al.  Extracorporeal Membrane Oxygenation (ECMO) in Critically Ill Patients with Coronavirus Disease 2019 (COVID-19) Pneumonia and Acute Respiratory Distress Syndrome (ARDS) , 2020, Medical science monitor : international medical journal of experimental and clinical research.

[19]  Andrea Gianatti,et al.  Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study , 2020, The Lancet Infectious Diseases.

[20]  M. Aepfelbacher,et al.  Dying with SARS-CoV-2 infection—an autopsy study of the first consecutive 80 cases in Hamburg, Germany , 2020, International Journal of Legal Medicine.

[21]  R. V. Vander Heide,et al.  Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans , 2020, The Lancet Respiratory Medicine.

[22]  M. Dolhnikoff,et al.  Pulmonary and systemic involvement in COVID‐19 patients assessed with ultrasound‐guided minimally invasive autopsy , 2020, Histopathology.

[23]  Guanzhen Wang,et al.  Preliminary study to identify severe from moderate cases of COVID-19 using combined hematology parameters , 2020, Annals of translational medicine.

[24]  Xiaosheng Wang,et al.  Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues , 2020, Infectious Diseases of Poverty.

[25]  Holger Moch,et al.  Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.

[26]  Yuan Yu,et al.  Thrombocytopenia and its association with mortality in patients with COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[27]  Theodora Psaltopoulou,et al.  Hematological findings and complications of COVID‐19 , 2020, American journal of hematology.

[28]  Jian-Ping Liu,et al.  The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients , 2020, International Immunopharmacology.

[29]  Xiao Chen,et al.  Platelet‐to‐lymphocyte ratio is associated with prognosis in patients with coronavirus disease‐19 , 2020, Journal of medical virology.

[30]  Qiu Zhao,et al.  Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  Mario Plebani,et al.  Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis , 2020, Clinica Chimica Acta.

[32]  G. B. Tan,et al.  Hematologic parameters in patients with COVID‐19 infection , 2020, American journal of hematology.

[33]  B. Arcagok,et al.  Platelet to Lymphocyte Ratio in Neonates: A Predictor of Early onset Neonatal Sepsis , 2019, Mediterranean journal of hematology and infectious diseases.

[34]  C. Hobbs,et al.  LPS-Induced Lung Platelet Recruitment Occurs Independently from Neutrophils, PSGL-1, and P-selectin. , 2019, American journal of respiratory cell and molecular biology.

[35]  S. Natsugoe,et al.  Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer , 2019, BMC cancer.

[36]  Xin Wang,et al.  Study on the Protective Effect of Special Electromagnetic Field Treated Water and Far Infrared Rays on LPS-Induced ARDS Rats , 2019, Evidence-based complementary and alternative medicine : eCAM.

[37]  A. Kurtul,et al.  Platelet to Lymphocyte Ratio in Cardiovascular Diseases: A Systematic Review , 2019, Angiology.

[38]  G. Kitas,et al.  The Platelet-to-Lymphocyte Ratio as an Inflammatory Marker in Rheumatic Diseases , 2019, Annals of laboratory medicine.

[39]  E. Lefrançais,et al.  Platelet Biogenesis in the Lung Circulation , 2018, Blood.

[40]  J. Heemskerk,et al.  Platelet biology and functions: new concepts and clinical perspectives , 2018, Nature Reviews Cardiology.

[41]  M. Surbatovic,et al.  Neutrophil-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Mean Platelet Volume-to-Platelet Count Ratio as Biomarkers in Critically Ill and Injured Patients: Which Ratio to Choose to Predict Outcome and Nature of Bacteremia? , 2018, Mediators of inflammation.

[42]  Jun-fen Ma,et al.  Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in acute pulmonary embolism: a systematic review and meta-analysis. , 2018, International angiology : a journal of the International Union of Angiology.

[43]  Ana E. Paiva,et al.  Lung as a Niche for Hematopoietic Progenitors , 2017, Stem Cell Reviews and Reports.

[44]  Stephanie Law,et al.  Evaluation of platelet lymphocyte ratio and 90-day mortality in patients with acute exacerbation of chronic obstructive pulmonary disease. , 2017, Journal of thoracic disease.

[45]  Yongjun Wei,et al.  Celastrol attenuates impairments associated with lipopolysaccharide-induced acute respiratory distress syndrome (ARDS) in rats , 2017, Journal of immunotoxicology.

[46]  S. Cai,et al.  Dexmedetomidine attenuates lipopolysaccharide-induced acute lung injury by inhibiting oxidative stress, mitochondrial dysfunction and apoptosis in rats , 2016, Molecular medicine reports.

[47]  J. Kang,et al.  Changes of hematological references depends on storage period and temperature conditions in rats and dogs , 2016, Laboratory animal research.

[48]  Haojun Fan,et al.  Therapeutic Effect of Intravenous Infusion of Perfluorocarbon Emulsion on LPS-Induced Acute Lung Injury in Rats , 2014, PloS one.

[49]  Nailin Li Platelet–lymphocyte cross‐talk , 2008, Journal of leukocyte biology.

[50]  E. Mark,et al.  Megakaryocytes and platelet homeostasis in diffuse alveolar damage. , 2007, Experimental and molecular pathology.

[51]  Chi-kong Li,et al.  Thrombocytopenia in patients with severe acute respiratory syndrome (review) , 2005, Hematology.

[52]  Chi-kong Li,et al.  Lung Damage May Induce Thrombocytopenia. , 2004, Blood.

[53]  Chi-kong Li,et al.  Hematological findings in SARS patients and possible mechanisms (review). , 2004, International journal of molecular medicine.

[54]  Feng Xu,et al.  Effects of Oxygen-Induced Lung Damage on Megakaryocytopoiesis and Platelet Homeostasis in a Rat Model , 2003, Pediatric Research.

[55]  P. Chan,et al.  Clinical presentations and outcome of severe acute respiratory syndrome in children , 2003, The Lancet.

[56]  J. Ellis,et al.  Platelet Survival Time in Patients with Hypoxemia and Pulmonary Hypertension , 1977, Circulation.

[57]  A. Kallinikos-Maniatis Megakaryocytes and platelets in central venous and arterial blood. , 1969, Acta haematologica.

[58]  W. H. Howell,et al.  THE PRODUCTION OF BLOOD PLATELETS IN THE LUNGS , 1937, The Journal of experimental medicine.